Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – (Nasdaq: ICGND) is getting a $5 million boost from drug giant Pfizer to continue joint research into potential drugs for pain relief and other disorders.

Icagen, which recently executed a reverse stock split, has worked with Pfizer over the past three years.

Pfizer is funding research with a $5 million commitment through December 2011.

If development milestones are met, Icagen would receive some $359 million.

Get the latest news alerts: at Twitter.